Skip to main content
micro-community-banner
 
  • Saved

Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma

Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma

Source : https://www.researchsquare.com/article/rs-146899/v1

Osteolytic lesions (OL) characterize symptomatic multiple myeloma. The mechanisms of how malignant plasma cells (PC) cause OL in one region while others show no signs of bone destruction despite subtotal .....

  • Saved

Reporter/Multiple Myeloma/car-t-cell-therapies-bispecific-antibodies-and-antibody-conjugates

CAR T-Cell Therapies, Bispecific Antibodies, and Antibody Conjugates

Source : https://expertperspectives.com/Conference

Aggressive B-Cell Non-Hodgkin Lymphoma: Molecular Profiling and Post-Treatment Surveillance

  • Saved

An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma

An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma

Source : https://doi.org/10.1080/14712598.2021.1872540

ABSTRACT Introduction: B-cell maturation antigen (BCMA) targeted therapy (BCMA-TT) has emerged as a promising treatment for Multiple Myeloma (MM). the three most common treatment modalities for targeting BCMA are antibody-drug .....

  • Saved

Imaging Techniques for Response Assessment and Follow-Up

Imaging Techniques for Response Assessment and Follow-Up

Source : https://link.springer.com/chapter/10.1007/978-3-030-63662-3_5

Leo Rasche Anke Heidemeier Stefan Delorme Niels Weinhold A recent study in newly diagnosed multiple myeloma (MM) patients revealed that high-risk tumor clones can be restricted to focal lesions (FLs) .....

  • Saved

New Perspectives in Imaging Techniques

New Perspectives in Imaging Techniques

Source : https://link.springer.com/chapter/10.1007/978-3-030-63662-3_6

Bastien Jamet Clément Bailly Thomas Carlier Anne-Victoire Michaud Cyrille Touzeau Philippe Moreau Caroline Bodet-Milin Françoise Kraeber-Bodéré The development of nuclear medicine offers new perspectives in multiple myeloma (MM) imaging. New .....

  • Saved

Treatment of Multiple Myeloma with Kidney Involvement

Treatment of Multiple Myeloma with Kidney Involvement

Source : https://link.springer.com/chapter/10.1007/978-3-030-63662-3_10

Mark A. Cook In many respects, the treatment of myeloma in patients with kidney involvement and renal impairment has the same goal as any other patient group being treated for .....

BCMA targeted immunotherapy for multiple myeloma

While the introduction of proteasome inhibitors, immunomodulators and monoclonal antibodies targeting CD38 have revolutionized the treatment of multiple myeloma, many patients become refractory to these agents. The B-cell maturation agent (BCMA) is expressed on 100% of plasma cells but not on immature hematopoietic cells or other normal tissue and has emerged as a novel target for immunotherapy in multiple myeloma. Agents targeting BCMA have been shown to significantly improve outcomes in triple-refractory patients. These agents include two CAR-T therapies, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), currently under regulatory review with the FDA for triple-refractory multiple myeloma and the antibody-drug conjugate belantamab mafodotin, approved in 2020 for patients who have received at least four prior therapies.

What factors will you consider when selecting a BCMA-directed therapy for triple-refractory patients? Are there certain groups of patients better suited for either an antibody-drug conjugate or a CAR-T therapy? Do you think anti-BCMA agents will eventually be used in earlier lines of therapy?

  • Saved

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

Source : https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3624

Abstract The low rate of durable response against relapsed and/or refractory multiple myeloma (RRMM) in recent studies indicates that chimeric antigen receptor T‐cell (CART) treatment is yet to be ...